Alzheimer's disease

A team of international researchers has developed a new drug that targets the two main sites of protein Tau accumulation, a key factor in neurodegeneration in Alzheimer’s disease. The research was published in the journal Alzheimer’s & Dementia, by the American Alzheimer’s Association.

Two Alzheimer's drugs, lecanemab and donanemab, have been approved in the US. At a recent gathering organized by the Goulandris Foundation and the Hellenic Initiative Against Alzheimer's, new research on lecanemab was presented.

Researchers from Columbia University, including a Turkish scientist, have discovered a genetic change that reduces the risk of Alzheimer's by 71 percent.

My father decided to start learning French when he was 57. He hired a tutor to meet with him twice a week and diligently completed his homework before every lesson. Before long, he was visiting the French bakery across town to practice his pronunciation (and buy macarons). Now, two decades later, he's on his third tutor.

A recent study published in the online edition of Neurology, the American Academy of Neurology's medical journal, suggests that disrupted sleep patterns in one's 30s and 40s could potentially lead to memory and cognitive issues a decade later.

The approval by the US Food and Drug Administration last Thursday of the antibody treatment Leqembi, which significantly slows the progression of Alzheimer's in its early stages, has given hope to millions of patients and their families. 

The drug is the fruit of the collaboration between American biotechnology company Biogen and Japan's Eisai.

WEESP, Netherlands - On a recent morning in this quiet village outside Amsterdam, an older woman stocked shelves inside the local supermarket. In the plaza just outside the store, a group of men sat around a table, chatting the hours away. Over in the town square, a woman in a hijab sipped coffee outside the cafe.

A Slovenian-German-Dutch team of scientists has identified a modification of a protein which plays a role in early-onset frontotemporal dementia, an important insight into the causes of the disease that could lead to the development of new strategies to treat it.

A Turkish neurology professor studying in the United States has received a $41 million government grant for her groundbreaking research on Alzheimer's disease and how it affects people of different ethnic groups.

Encouraging results have emerged from the multi-year research of a team of scientists at the Demokritos National Center of Scientific Research giving hope of future tools for the better treatment of conditions that affect the central nervous system, such as Alzheimer's disease and malignant brain tumors.